SCHEMBL13282917

SCHEMBL13282917

Cc1csc2c(=O)n(NC(=O)Cc3ccc(F)cc3)c(SC(C)C)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 7/20 0.39
LMNA P02545 4/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.38
TGM2 P21980 1/20 0.37
PRKACA P17612 1/20 0.37
ROCK1 Q13464 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
WNT3A P56704 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378677 0.89 PRKACA (0.40) RAB9ANPSR1KMT2ALMNAMEN1
SCHEMBL3414928 0.79 NPSR1 (0.45) RAB9ANPC1NPSR1KMT2ALMNA
SCHEMBL13282913 0.77 NPSR1 (0.61) RAB9ANPSR1KMT2ALMNAMEN1
SCHEMBL13283002 0.77 RAB9A (0.48) RAB9ANPC1NPSR1KMT2ALMNA
SCHEMBL13283000 0.75 NPSR1 (0.44) RAB9ANPSR1KMT2ALMNAMEN1
SCHEMBL13283005 0.75 RAB9A (0.45) RAB9ANPSR1KMT2ALMNAMEN1
SCHEMBL13282995 0.72 NPSR1 (0.52) RAB9ANPC1NPSR1KDM4EKMT2A
SCHEMBL3380682 0.71 NPSR1 (0.56) RAB9ANPC1NPSR1KDM4EKMT2A
SCHEMBL13282878 0.70 RAB9A (0.43) RAB9ANPSR1KMT2ALMNAMEN1
SCHEMBL3381133 0.69 RAB9A (0.48) RAB9ANPC1NPSR1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 RAB9A 560/4885NPC1 921/4885NPSR1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.